Bevacizumab biosimilar (Intas Pharmaceuticals)

Product Name :
Bevacizumab biosimilar (Intas Pharmaceuticals)

Search keywords :
G-1

drugId :
null

Target Vo:
Vascular endothelial growth factor A

Target Vo Short Name :
VEGFA

Moa_Name:
Angiogenesis inhibitors

First Approval Country :
India

First Approval Date Filter:
2017

Origin Company_Name :
Intas Biopharmaceuticals

Active Company_Name :
Intas Biopharmaceuticals

Active Indication_Name:
Carcinoma, Non-Small-Cell Lung

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
HSP60 Mouse mAb Purity & Documentation
Glutaminase Rabbit mAb web
S100A4 Antibody: S100A4 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 12 kDa, targeting to S100A4. It can be used for WB,ICC/IF,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse.

Author: Betaine hydrochloride

Related Posts